Showing results (161-170 of 378) with videos related to
Sort By:
Pageof 38
Cellular Reprogramming|July 2, 2011
Feline bone marrow-derived mesenchymal stem cells express several pluripotent and neural markers and easily turn into neural-like cells by manipulation with chromatin modifying agents and neural inducing factorsZhiying Zhang, Dennis J Maiman, Shekar N Kurpad, et al.Cancer Treatment Reports|June 1, 1982
Vincristine, BCNU, doxorubicin, and prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group studyJ Bonnet, R Alexanian, S Salmon, et al.Blood|December 1, 1988
Prognostic factors with high-dose melphalan for refractory multiple myelomaB Barlogie, R Alexanian, L Smallwood, et al.Blood|September 1, 1987
High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myelomaB Barlogie, R Alexanian, K A Dicke, et al.Annals of Hematology|August 20, 2002
Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in GreeceA Anagnostopoulos, A Evangelopoulou, D Sotou, et al.The Journal of Urology|March 17, 2004
Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced bladder cancer: a study by the Hellenic Cooperative Oncology GroupA Bamias, Ch Deliveliotis, G Aravantinos, et al.Journal D'Urologie|January 1, 1983
[Genetic markers in papillary cancer of the bladder]M A Dimopoulos, A Germenis, P Savides, et al.Immunotherapy|September 15, 2011
An overview of the VISTA trial: newly diagnosed, untreated patients with multiple myeloma ineligible for stem cell transplantationIvan Spicka, M V Mateos, K Redman, et al.Human Pathology|March 7, 1998
The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlatesL Nakopoulou, C Vourlakou, A Zervas, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 2, 1999
Clinical course of solitary extramedullary plasmacytomaR H Liebross, C S Ha, J D Cox, et al.Pageof 38